Bausch + Lomb unveils new ESCRS clinical data on enVista Aspire, LuxLife IOLs, ELIOS glaucoma procedurePUBT·Sep 3 at 11:12 AMBLCO+0.34%
Bausch + Lomb study finds enVista Aspire IOLs deliver strong distance, intermediate vision in real-world usePUBT·Sep 2 at 11:00 AMBLCO+0.34%
Bausch + Lomb advances dual-action dry eye drop into Phase 3 after Phase 2 Day 15 endpoint winPUBT·Aug 24 at 08:31 PMBLCO+0.34%
Bausch + Lomb files Form 3 disclosing director Thomas Appio stake of 27,583 sharesPUBT·Aug 14 at 09:13 PMBLCO+0.34%
Bausch + Lomb SVP, Controller and CAO Frederick Munsch sells 52,900 common shares worth $887,662PUBT·Aug 12 at 11:07 PMBLCO+0.34%
Bausch + Lomb names Thomas Appio board chair in amended filing, replacing Brent SaundersPUBT·Aug 12 at 11:04 AMBLCO+0.34%
Bausch + Lomb (NYSE:BLCO) Director Eschenbach Andrew Von Sells 12,500 SharesMarket Beat·Aug 11 at 03:07 AMBLCO+0.34%
Bausch + Lomb director Andrew C. von Eschenbach sells 18,559 common shares for $306,709.22PUBT·Aug 11 at 12:58 AMBLCO+0.34%
